113 related articles for article (PubMed ID: 11602817)
1. Effects of E047/1, a new antiarrhythmic drug, on experimental atrial fibrillation in anesthetized dogs.
Sharifov OF; Fedorov VV; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2001 Nov; 38(5):706-14. PubMed ID: 11602817
[TBL] [Abstract][Full Text] [Related]
2. [Antiarrhythmic Efficacy of a New Class III Antiarrhythmic Drug RG-2.].
Fedorov VV; Rozenshtraukh LV; Reznik AV; Beloshapko GG; Iushmanova AV; Golitsyn SP; Ruda MIa; Chazov EI
Kardiologiia; 2004; 44(11):66-73. PubMed ID: 15602444
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic Effects of the New Class III Antiarrhythmic Drug Dofetilide in an Experimental Canine Model of Pacing-induced Atrial Fibrillation.
Feld GK; Cha Y
J Cardiovasc Pharmacol Ther; 1997 Jul; 2(3):195-203. PubMed ID: 10684458
[TBL] [Abstract][Full Text] [Related]
4. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
[TBL] [Abstract][Full Text] [Related]
6. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
[TBL] [Abstract][Full Text] [Related]
7. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Iwasa A; Okumura K; Tabuchi T; Tsuchiya T; Tsunoda R; Matsunaga T; Tayama S; Yasue H
Eur J Pharmacol; 1998 Aug; 356(1):31-40. PubMed ID: 9761421
[TBL] [Abstract][Full Text] [Related]
8. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
Nattel S; Liu L; St-Georges D
Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
[TBL] [Abstract][Full Text] [Related]
9. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model.
Goldstein RN; Khrestian C; Carlsson L; Waldo AL
J Cardiovasc Electrophysiol; 2004 Dec; 15(12):1444-50. PubMed ID: 15610294
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation.
Rahme MM; Cotter B; Leistad E; Wadhwa MK; Mohabir R; Ford AP; Eglen RM; Feld GK
Circulation; 1999 Nov; 100(19):2010-7. PubMed ID: 10556228
[TBL] [Abstract][Full Text] [Related]
11. The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.
Derakhchan K; Villemaire C; Talajic M; Nattel S
Cardiovasc Res; 2001 Apr; 50(1):75-84. PubMed ID: 11282080
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs.
Kirchhof C; Wijffels M; Brugada J; Planellas J; Allessie M
J Cardiovasc Pharmacol; 1991 Jan; 17(1):116-24. PubMed ID: 1708044
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias.
Fujiki A; Tani M; Mizumaki K; Shimono M; Inoue H
J Cardiovasc Pharmacol; 1994 Mar; 23(3):374-8. PubMed ID: 7515979
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
[TBL] [Abstract][Full Text] [Related]
15. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Inoue H; Yamashita T; Nozaki A; Sugimoto T
J Am Coll Cardiol; 1991 Oct; 18(4):1098-104. PubMed ID: 1910060
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine terminates atrial flutter and fibrillation in a canine model.
Bhimani AA; Yasuda T; Sadrpour SA; Khrestian CM; Lee S; Zeng D; Belardinelli L; Waldo AL
Heart Rhythm; 2014 Sep; 11(9):1592-9. PubMed ID: 25066042
[TBL] [Abstract][Full Text] [Related]
17. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
Zuanetti G; Corr PB
J Pharmacol Exp Ther; 1991 Jan; 256(1):325-34. PubMed ID: 1988663
[TBL] [Abstract][Full Text] [Related]
19. Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
Yamamoto W; Hashimoto N; Matsuura J; Machida T; Ogino Y; Kobayashi T; Yamanaka Y; Ishiwata N; Yamashita T; Tanimoto K; Miyoshi S; Fukuda K; Nakaya H; Ogawa S
J Cardiovasc Pharmacol; 2014 May; 63(5):421-7. PubMed ID: 24805146
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model.
Shimizu A; Kaibara M; Centurion OA; Kapuku G; Hirata T; Fukatani M; Yano K; Hashiba K
J Cardiovasc Pharmacol; 1993 Apr; 21(4):656-62. PubMed ID: 7681913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
